Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access the Akari CEO Corner here TAMPA, Fla. and ...

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

Total revenue of Junshi Biosciences was approximately RMB2,498 million in 2025, representing an increase of approximately 28% compared to 2024, which was mainly due to the increase in revenue from ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.

TOKYO, March 12, 2026 3 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in ...

Will advance the biotech company's lead antibody-drug conjugate (ADC) program.

A month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 2.8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, ...

The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...

Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?